Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

98.45 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
Via InvestorPlace
Topics Economy
Exposures Economy
Novartis Stock Generating Improved Relative Strength
Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis... 
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
Exploring NYSE:NVS's dividend characteristics.
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock. 
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients
A Mississippi judge upheld a state law requiring drugmakers to offer discounts on medications through third-party pharmacies for low-income populations, rejecting lawsuits from PhRMA and Novartis. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs
With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland. 
Via News Direct
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry. 
Via Investor's Business Daily
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media. 
Via Benzinga
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
What's Going On With Neurological Disease Focused Trevena On Thursday?
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod. 
Via Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis. 
Via Benzinga
Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD Today
Via Get News
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. 
Via InvestorPlace
Novartis Sues to Block Maryland's New Drug Discount Law
Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharmacies contracting with hospitals and clinics. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety
Novartis reveals Phase 3 data confirming remibrutinib's long-term efficacy and safety for chronic spontaneous urticaria, showing significant symptom improvement and a favorable safety profile up to... 
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
Exposures Information Security
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors. 
Via The Motley Fool
The 3 Best Mutual Funds to Buy in May 2024
Consider the best mutual funds to buy for high returns and low fees. They each have unique strategies meant to maximize returns on capital. 
Via InvestorPlace
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga
3 Biotech Stocks to Sell in May Before They Crash & Burn
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Axmed raises $2 million to transform access to critical medicines in low and middle income countries
Axmed’s B2B marketplace aggregates demand for critical medicines in underserved regions to improve the availability, affordability, and distribution of life-saving medicine. 
Via News Direct
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.